On this page
What it is
What Is Tirzepatide?Tirzepatide is a synthetic peptide developed by Eli Lilly that simultaneously activates two incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It's sold under two brand names:
What people research it for
What is tirzepatide?
Human studiesTirzepatide is a dual GIP/GLP-1 receptor agonist — the first medication to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. It is the active ingredient in Zepbound (weight loss) and Mounjaro (type 2 diabetes), both made by Eli Lilly.
How much weight can you lose on tirzepatide?
Human studiesThe SURMOUNT-1 trial showed an average of ~22.5% body weight loss at the 15 mg dose over 72 weeks — the highest weight loss ever recorded in a phase 3 obesity trial at the time of publication.
Is tirzepatide better than semaglutide?
Human studiesIn the SURMOUNT-5 head-to-head trial, tirzepatide produced 47% more weight loss than semaglutide (20.2% vs. 13.7%) and had fewer GI-related discontinuations. For most people without contraindications, tirzepatide appears to be the more effective option.
How it works
How Does Tirzepatide Work?Tirzepatide is structurally based on the native GIP hormone sequence (39 amino acids) and engineered to activate both GIP and GLP-1 receptors. This dual mechanism is what sets it apart from semaglutide (which only targets GLP-1).
GLP-1 Receptor Activation
Suppresses appetite via hypothalamic signaling, delays gastric emptying (so you feel full longer), enhances glucose-dependent insulin secretion, and reduces glucagon secretion. These are the same pathways semaglutide uses.
GIP Receptor Activation — The Added Dimension
GIP enhances the appetite-suppressing effects of GLP-1, improves insulin sensitivity, may promote fat oxidation (burning stored fat more efficiently), and contributes to improved metabolic regulation. This is the dimension semaglutide is missing.
“Imbalanced” Agonism
Tirzepatide has a unique pharmacological profile: it binds to the GIP receptor with equal affinity to natural GIP, but binds the GLP-1 receptor about 5-fold weaker than natural GLP-1. Despite the weaker GLP-1 binding, the combination of both pathways produces superior weight loss — suggesting that GIP activation adds something the GLP-1 pathway alone can't deliver.
The net effect: Two hormonal pathways working together to suppress appetite, slow digestion, improve insulin function, and enhance fat metabolism — producing significantly more weight loss than GLP-1-only medications.
What the research actually shows
Tirzepatide's weight loss efficacy has been studied in the SURMOUNT trial program — and most recently in a direct head-to-head trial against semaglutide.
Published
NEJM, 2022
Guide status and key facts
Key Facts at a Glance
- Drug class
- Dual GIP/GLP-1 receptor agonist
- Administration
- Once-weekly subcutaneous injection
- FDA approval
- Mounjaro: diabetes + CV risk; Zepbound: weight management
- Average loss
- ~22.5% body weight (72 wks, SURMOUNT-1)
- Manufacturer
- Eli Lilly
- Available doses
- 2.5, 5, 7.5, 10, 12.5, and 15 mg
Mounjaro Cardiovascular Indication: What Changed in August 2026
The FDA now indicates Mounjaro to reduce major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. The endpoint includes cardiovascular death, nonfatal heart attack, and nonfatal stroke. This was added to Mounjaro's existing blood-sugar indication in August 2026.
SURPASS-CVOT: Mounjaro vs. Trulicity
Randomized
13,299 adults
Population
Type 2 diabetes + established ASCVD
Median follow-up
210.1 weeks
| Primary MACE-3 result | Tirzepatide | Dulaglutide |
|---|---|---|
| People with an event | 801 (12.2%) | 862 (13.1%) |
| Absolute difference | 0.9 percentage points lower | Reference |
| Relative comparison | HR 0.92 | 95.3% CI 0.83 to 1.01 |
The hazard ratio corresponds to an 8% lower event rate with tirzepatide relative to dulaglutide. Tirzepatide met the prespecified test for noninferiority (P=0.003), but it did not establish superiority over dulaglutide (P=0.09). Dulaglutide was an active comparator with a proven cardiovascular benefit, not a placebo.
The peer-reviewed primary analysis excluded 134 randomized participants who did not meet eligibility criteria. The current Mounjaro label separately reports the all-randomized-and-treated analysis as 803 of 6,647 (12.1%) with Mounjaro versus 863 of 6,647 (13.0%) with dulaglutide. Both analyses support the same noninferiority conclusion.
Mounjaro vs. Zepbound
Both brands contain tirzepatide, but FDA indications attach to the branded product and population studied. Mounjaro has the type 2 diabetes and cardiovascular-risk indications. Zepbound's label covers chronic weight management and obstructive sleep apnea, not cardiovascular event reduction.
Safety context
Overall adverse-event incidence appeared similar between groups in the published trial, although gastrointestinal events were more frequent with tirzepatide. The current label retains its boxed thyroid C-cell tumor warning and warnings for pancreatitis, severe gastrointestinal reactions, hypoglycemia with insulin or secretagogues, gallbladder disease, and other risks described in the side-effects section.
What buyers should carry forward
SURPASS-CVOT tested branded tirzepatide under controlled trial conditions. It does not prove that a research-market vial has the stated identity, strength, purity, or clinical performance. Compare the current tirzepatide price per mg, then check the seller's batch-matched identity, purity, and fill-quantity evidence in the vendor directory before buying.
Clinical Trial Evidence
Tirzepatide's weight loss efficacy has been studied in the SURMOUNT trial program — and most recently in a direct head-to-head trial against semaglutide.
SURMOUNT-1 — The Landmark Obesity Trial
Published
NEJM, 2022
Participants
2,539 adults
Duration
72 weeks
Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, WITHOUT diabetes. Three tirzepatide doses vs. placebo.
| Dose | Avg. Loss | ≥5% Loss | ≥10% Loss | ≥20% Loss |
|---|---|---|---|---|
| 5 mg | 16.0% | 85% | 69% | 32% |
| 10 mg | 21.4% | 89% | 82% | 54% |
| 15 mg | 22.5% | 91% | 86% | 63% |
| Placebo | 3.1% | 35% | 14% | 1.3% |
For a 250-pound person on the highest dose, that's roughly 56 pounds lost over 72 weeks.
| Trial | Population | Avg. Loss | Key Finding |
|---|---|---|---|
| SURMOUNT-2 | Obesity + T2 diabetes | 14.7% | Strong results even with diabetes; still outperforms semaglutide |
| SURMOUNT-3 | After intensive lifestyle intervention | +21.1% | Added on top of lifestyle loss; total loss reached 26.6% |
| SURMOUNT-4 | Discontinuation study | — | Stopping = regaining ~14% body weight; weight loss maintained with continued use |
| SURMOUNT-5 | Head-to-head vs. semaglutide | 20.2% | 47% more weight loss than semaglutide (13.7%); published NEJM 2025 |
| SURMOUNT-MAINTAIN | Maintenance after plateau | 21.9% | At week 112, continued maximum tolerated dose maintained more loss than 5 mg or placebo |
SURMOUNT-5: Head-to-Head vs. Semaglutide (2025)
Published
NEJM, 2025
Participants
751 adults
Duration
72 weeks
The first large-scale, randomized, head-to-head trial comparing tirzepatide directly to semaglutide. No placebo — both groups received active treatment at maximum tolerated doses.
| Metric | Tirzepatide | Semaglutide |
|---|---|---|
| Avg. weight loss | 20.2% | 13.7% |
| Avg. weight lost | 22.8 kg (50.3 lbs) | 15.0 kg (33.1 lbs) |
| Waist circumference | −18.4 cm | −13.0 cm |
| GI discontinuation rate | 2.7% | 5.6% |
Source: Aronne LJ, et al. N Engl J Med. 2025;393(1):26-36.
What the SURMOUNT trials tell us:
- Average loss of 22.5% at max dose — nearly one-quarter of body weight
- 63% of patients at 15 mg lost ≥20% of body weight
- Works even in patients with type 2 diabetes (though results are lower)
- Stacks powerfully with behavioral lifestyle changes
- Weight returns significantly when treatment stops
- Outperformed semaglutide by 47% in direct head-to-head trial
Real-World Evidence
Clinical trials are conducted under strict conditions — controlled diets, frequent monitoring, motivated participants. Two large real-world studies now provide answers about what happens when regular people use tirzepatide in everyday life, and the results are encouraging: tirzepatide delivers meaningful weight loss outside of trial settings, though the patterns differ in important ways.
Optum Market Clarity Study (2025) — 20,998 Patients
The largest real-world tirzepatide study to date, analyzing patients without type 2 diabetes using linked pharmacy claims and electronic health records across the US.
| Metric | Result (6 months) |
|---|---|
| Mean weight loss | 11.9% |
| Achieved ≥5% loss | 85.8% |
| Achieved ≥10% loss | 61.5% |
| Persistence at 6 months | 55.4% |
| On <10 mg by 6th fill | 74.2% |
Key takeaways:
- Dose escalation is much slower in practice — 74% were still below 10 mg by their 6th fill
- Despite lower doses, meaningful weight loss still occurred
- Only 55.4% were still taking tirzepatide at 6 months — adherence is a real challenge
- 81% prescribed by primary care physicians — not obesity specialists
Source: Hankosky ER, et al. Diabetes Obes Metab. 2025;27(5):2634-2643.
SHAPE Study — 1-Year Real-World Comparison (2025)
Compared real-world outcomes for 9,916 patients — 6,794 on semaglutide 2.4 mg and 3,122 on tirzepatide — over a full year of continuous treatment using the Komodo Health database.
| Metric | Tirzepatide | Semaglutide 2.4 mg |
|---|---|---|
| Mean weight loss | −17.2 kg (37.9 lbs) | −14.6 kg (32.2 lbs) |
| Mean % weight loss | −16.5% | −14.1% |
| Reached max dose | 25.9% (15 mg) | 83.5% (2.4 mg) |
The striking finding: Only 25.9% of tirzepatide users reached the maximum 15 mg dose during the year, yet they still achieved 16.5% weight loss — suggesting significant room for further dose escalation in real-world use.
Source: Garvey WT, et al. Adv Ther. 2025.
Trials vs. Reality: What to Expect
| Metric | SURMOUNT-1 | Real-World (6 mo) | Real-World (12 mo) |
|---|---|---|---|
| Avg. weight loss | 22.5% (72 wks, 15 mg) | 11.9% | 16.5% |
| ≥5% achieved | 91% | 85.8% | — |
| Persistence | ~90% (trial) | 55.4% | 100% (persistent only) |
| Dose reached | 15 mg (protocol) | <10 mg in 74% | 15 mg in only 26% |
Bottom line:
Expect somewhat lower weight loss than clinical trials — mostly because real-world dose escalation is slower and adherence is harder. But for people who stick with treatment, results are impressive and clinically meaningful. And because most real-world patients haven't hit maximum dose yet, there's often more room to go.
Tirzepatide vs. Semaglutide: Quick Comparison
| Tirzepatide | Semaglutide | |
|---|---|---|
| Mechanism | GLP-1 + GIP (dual) | GLP-1 only |
| Avg. Weight Loss (head-to-head) | 20.2% | 13.7% |
| Max Dose | 15 mg/week | 2.4 mg/week (7.2 mg HD) |
| Brand Names | Mounjaro, Zepbound | Ozempic, Wegovy |
| GI Discontinuation Rate | 2.7% | 5.6% |
| FDA Approved (Weight Loss) | ✅ Nov 2023 | ✅ Jun 2021 |
Handling & storage
Storage at a glance
FDA label- Reconstituted
- 2 to 8°C
- Use within single-dose vial or pen: use as supplied; multidose KwikPen instructions are product-specific
- Do not reconstitute the approved single-dose product.
- Light
- Store in the original carton to protect from light. Do not freeze.
- Room temperature
- Single-dose pen or vial may be kept at no more than 30°C for a total of 21 days. Do not return it to the refrigerator after room-temperature storage unless the current product label explicitly allows it.
- Reconstitution
- Follow product-specific instructions
- Not applicable to approved solution products.
- Half-life
- about 5 days
- humans after subcutaneous administration
Basis: FDA label. Sources: DailyMed MOUNJARO label, DailyMed ZEPBOUND label
MOUNJARO and ZEPBOUND single-dose pens and vials are approved solution products. Store them at 2 to 8°C in the original carton, protect them from light, and do not freeze. The approved single-dose presentation may stay at no more than 30°C for a total of 21 days.
These numbers belong to the named Lilly products. Compounded or research powders and multidose vials need their own pharmacy or supplier instructions; the branded label does not create a beyond-use date for them. Tirzepatide has a human half-life of about 5 days after subcutaneous administration.
Safety & cautions
Tirzepatide's side effect profile is similar to semaglutide, with mostly GI-related symptoms. Notably, in the SURMOUNT-5 head-to-head trial, fewer tirzepatide users discontinued due to GI side effects compared to semaglutide (2.7% vs. 5.6%).
FDA Black Box Warning: Like semaglutide, tirzepatide carries a black box warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
Long-Term Maintenance Evidence
The short answer: tirzepatide has moved beyond 72-week weight-loss trials. The best long-term data now support two ideas at once. Continued treatment can maintain large weight reductions for years, and stopping or sharply reducing treatment intensity can lead to partial regain. That does not mean every person needs the same dose forever. It does mean maintenance is a treatment phase, not an afterthought.
3-Year SURMOUNT-1 Prediabetes Follow-Up
Jastreboff and colleagues reported the 176-week SURMOUNT-1 extension in the New England Journal of Medicine in 2025. In 1,032 adults with obesity and prediabetes, tirzepatide produced sustained weight loss through three years:
- 5 mg:12.3% mean weight loss at week 176
- 10 mg:18.7% mean weight loss at week 176
- 15 mg:19.7% mean weight loss at week 176
- Placebo:1.3% mean weight loss at week 176
Type 2 diabetes was diagnosed in 1.3% of tirzepatide-treated participants versus 13.3% with placebo during the 176-week period. No new safety signals were identified.
SURMOUNT-MAINTAIN: Dedicated Maintenance Trial
Horn and colleagues published SURMOUNT-MAINTAIN in The Lancet in May 2026. The trial enrolled 441 adults in a 60-week open-label tirzepatide weight-loss period, then randomized 378 responders to continue maximum tolerated dose, reduce to 5 mg, or switch to placebo for maintenance.
| Week 112 result | Weight change |
|---|---|
| Continued 10 or 15 mg | -21.9% |
| Reduced to 5 mg | -16.6% |
| Switched to placebo | -9.9% |
Regain of at least half the lost weight occurred in 8% on maximum tolerated dose, 25% on 5 mg, and 67% on placebo.
What this means in practice
Tirzepatide maintenance is not a simple on/off question. The 2026 data suggest some people may maintain meaningful loss on lower-intensity treatment, but the maximum tolerated dose preserved more weight loss than 5 mg, and both active treatment arms did better than placebo. Dose changes should be handled by the prescribing clinician, based on response, side effects, comorbidities, cost, and access.
For more on regain after stopping and the broader GLP-1 maintenance problem, read our guide to what happens when you stop GLP-1 drugs.
Dosing Protocol
Tirzepatide uses a gradual escalation over 20+ weeks, similar to semaglutide but with more dose steps. The 2.5 mg starting dose is for initiation only — it's not an effective maintenance dose.
Standard Zepbound Escalation Schedule
| Weeks | Weekly Dose | Purpose |
|---|---|---|
| 1–4 | 2.5 mg | Initiation only — NOT a maintenance dose |
| 5–8 | 5 mg | First maintenance dose option |
| 9–12 | 7.5 mg | Optional increase |
| 13–16 | 10 mg | Second maintenance dose option |
| 17–20 | 12.5 mg | Optional increase |
| 21+ | 15 mg | Maximum dose |
Important dosing notes:
- The 2.5 mg starting dose is for initiation only — minimum effective maintenance dose is 5 mg
- Many people achieve good results at 10 mg without needing 15 mg
- Each dose increase may temporarily worsen GI side effects
- Your doctor may keep you at a lower dose if you're responding well
- Inject subcutaneously: abdomen, thigh, or upper arm
- Same day each week, with or without food
Side Effects
Tirzepatide's side effect profile is similar to semaglutide, with mostly GI-related symptoms. Notably, in the SURMOUNT-5 head-to-head trial, fewer tirzepatide users discontinued due to GI side effects compared to semaglutide (2.7% vs. 5.6%).
Common Side Effects (>10% of patients)
- NauseaMost common; peaks during dose escalation
- Diarrhea
- Decreased appetitePartly how it works
- Vomiting
- Constipation
- Abdominal pain
Less Common Side Effects (1–10%)
- •Indigestion / heartburn
- •Burping / flatulence
- •Injection site reactions
- •Fatigue
- •Hair thinning (rapid weight loss)
- •Dizziness
Serious Side Effects (Rare but Important)
- Pancreatitis — Seek immediate care for severe, persistent abdominal pain
- Gallbladder problems — Rapid weight loss increases gallstone risk
- Kidney injury — Usually from dehydration due to vomiting/diarrhea
- Hypoglycemia — Risk increases if combined with insulin or sulfonylureas
- Allergic reactions — Rare; discontinue and seek care if they occur
FDA Black Box Warning
Like semaglutide, tirzepatide carries a black box warning for thyroid C-cell tumors based on rodent studies. Contraindicated in people with personal/family history of medullary thyroid carcinoma or MEN 2 syndrome.
Cost & Access
| Option | Brand | Typical Cost/Month |
|---|---|---|
| Zepbound (weight loss) | Eli Lilly | ~$1,069 list price |
| Zepbound (savings card) | Eli Lilly | As low as $25 |
| Mounjaro (diabetes) | Eli Lilly | Similar to Zepbound |
| Compounded tirzepatide | Various providers | $349–$699 |
How to Access Tirzepatide
- Talk to your doctor or use a telehealth platform
- Eligible criteria: BMI ≥30, or ≥27 with a weight-related condition
- If prescribed, fill through pharmacy or telehealth partner
- Check Eli Lilly's savings programs — significant discounts available for commercially insured patients
Compounded tirzepatide is available through telehealth providers during FDA shortage periods. Legal status is evolving — choose providers using FDA-registered compounding pharmacies. See our compounded vs. brand guide for a full breakdown and our tips on getting GLP-1 medications without insurance.
How to Get Tirzepatide
Tirzepatide requires a prescription. The most accessible route for most people is a telehealth provider. Below are platforms that currently offer tirzepatide prescriptions.
PeptidePub may earn a commission from links below. See disclosure.
SkinnyRx
Compounded injectable tirzepatide and GLP-1 program options
Dedicated tirzepatide landing page plus broader GLP-1 medication options
Direct Meds
Quiz-based GLP-1 intake flow
Useful for visitors who want guided intake before seeing GLP-1 options
See our full provider comparison for more detail on pricing, what's included, and how to choose.
Watch Tirzepatide prices
We'll email you when prices drop, a discount code changes, or new lab results come in for Tirzepatide. No spam — only real changes.
Frequently asked questions
What is tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first medication to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. It is the active ingredient in Zepbound (weight loss) and Mounjaro (type 2 diabetes), both made by Eli Lilly.
How much weight can you lose on tirzepatide?
The SURMOUNT-1 trial showed an average of ~22.5% body weight loss at the 15 mg dose over 72 weeks — the highest weight loss ever recorded in a phase 3 obesity trial at the time of publication.
Is tirzepatide better than semaglutide?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced 47% more weight loss than semaglutide (20.2% vs. 13.7%) and had fewer GI-related discontinuations. For most people without contraindications, tirzepatide appears to be the more effective option.
What are tirzepatide side effects?
Side effects are similar to semaglutide: nausea, vomiting, diarrhea, and constipation are the most common. Tirzepatide showed fewer GI-related treatment discontinuations than semaglutide in the SURMOUNT-5 head-to-head trial, suggesting somewhat better tolerability for most patients.
Does Mounjaro have an FDA cardiovascular indication?
Yes. Since August 2026, Mounjaro has been indicated to reduce cardiovascular death, nonfatal heart attack, or nonfatal stroke in adults with type 2 diabetes who are at high risk for these events. In SURPASS-CVOT, tirzepatide was noninferior to dulaglutide for this three-part cardiovascular endpoint; superiority was not established.
How much does tirzepatide cost?
Brand-name Zepbound costs approximately $1,069/month at list price without insurance. Compounded tirzepatide from 503B-registered pharmacies through telehealth platforms typically costs $249–$349/month. With insurance coverage or Lilly savings programs, brand-name costs can be reduced.
The Bottom Line
Tirzepatide represents the current gold standard in FDA-approved weight loss medications. Its dual GIP/GLP-1 mechanism delivers significantly more weight loss than semaglutide — confirmed in a head-to-head trial published in the New England Journal of Medicine.
With average weight loss exceeding 20% of body weight and a generally favorable side effect profile, tirzepatide has set a new benchmark. The main barriers remain cost and access, though compounded versions and insurance coverage are expanding. For people who haven't responded adequately to semaglutide, or who want the most effective currently approved option, tirzepatide is the leading choice.
Source details
- 1.Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(4):327-340.
- 2.Garvey WT, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." Lancet. 2023;402(10402):613-626.
- 3.Wadden TA, et al. "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)." Nat Med. 2024;30:735-744.
- 4.Aronne LJ, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4)." JAMA. 2024;331(1):38-48.
- 5.Aronne LJ, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)." N Engl J Med. 2025;393(1):26-36.
- 6.Nicholls SJ, et al. "Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT)." N Engl J Med. 2025;393(24):2409-2420.
- 7.Mounjaro (tirzepatide) U.S. Prescribing Information. Eli Lilly and Company. Revised August 2026.
- 8.Eli Lilly and Company. "FDA Approves Lilly's Mounjaro (tirzepatide) to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes." August 28, 2026.
- 9.Jastreboff AM, et al. "Tirzepatide for Obesity Treatment and Diabetes Prevention." N Engl J Med. 2025;392(10):958-971.
- 10.Horn DB, et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN)." Lancet. Published online May 12, 2026.
- 11.Thomas MK, et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight. 2020;5(17):e140532.
- 12."Tirzepatide - StatPearls." NCBI Bookshelf. Updated 2024.
- 13.Hankosky ER, et al. "Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes." Diabetes Obes Metab. 2025;27(5):2634-2643.
- 14.Garvey WT, et al. "Real-World Weight Loss Observed With Semaglutide and Tirzepatide (SHAPE)." Adv Ther. 2025.
Research updates
Stay Updated on Peptide Research
New trial results, FDA updates, and dosing guides — delivered to your inbox.
Medical disclaimer
Sources
Last reviewed September 1, 2026. This guide is educational and research-focused, not medical advice. Tirzepatide products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
GO DEEPER
This guide covers one compound. We wrote the book on all 45.
The Peptide Handbook takes everything we know from testing vendors for a living and turns it into five readable books: what each compound actually does, what the evidence really says, and the honest call when the answer is "skip this one." Plus the dosing tables, calendars, and trackers that make it usable.